Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach

Vaccine

Volumn 21, Issue 27-30, 2003, Pages 4486-4504

  De Groot, Anne S ^a,b   Jesdale, Bill ^a   Martin, William ^b   Saint Aubin, Caitlin ^a   Sbai, Hakima ^a   Bosma, Andrew ^a   Lieberman, Judy ^c   Skowron, Gail ^d   Mansourati, Fadi ^e   Mayer, Kenneth H ^e  

^a BROWN UNIVERSITY   (United States)

^b EpiVax Inc   (United States)

^c CENTER FOR BLOOD RESEARCH   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

^e Brown University AIDS Program   (United States)

Author keywords

Cytotoxic T cell; Epitope; HIV 1 vaccine; Imminoformatics

Indexed keywords

GAMMA INTERFERON; HLA A ANTIGEN; HLA B ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ALLELE; ARTICLE; BIOINFORMATICS; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; EPITOPE MAPPING; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY;

EID: 10744231197     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00390-6     Document Type: Article

References (53)

1. Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W.et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:1997;3389-3402.
2. Bairoch A. Amino acid scale: amino acid composition (%) in the SWISS-PROT protein sequence data bank. SWISS-PROT release 38; 1999 [online].
3. Bende S., Johnston M. Immunization update: search for an AIDS vaccine. AIDS Read. 10:2000;526.
4. Korber B, Meyers G. Los Alamos HIV sequence database. Los Alamos (NM): Los Alamos National Laboratories; 2002 [online].
5. Korber B, Meyers G. Los Alamos HIV sequence database. Los Alamos (NM): Los Alamos National Laboratories; 1997 [online].
6. Betts M.R., Casazza J.P., Patterson B.A., Waldrop S., Trigona W., Fu T.M.et al. Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype. J. Virol. 74:2000;9144-9151.
7. Bond K., Pau C.P., Malegam J.Y., De Groot A.S., Szu E., Hodge T.W.et al. HLA A11 cytotoxic T lymphocyte epitopes in HIV-1 env subtype E. AIDS Res. Hum. Retroviruses. 17:2001;703-718.
8. Brander C., Pichler W.J., Corradin G. Identification of HIV protein-derived cytotoxic T lymphocyte (CTL) epitopes for their possible use as synthetic vaccine. Clin. Exp. Immunol. 101:1995;107-113.
9. Brander C, Walker BD. The HLA class I restricted CTL response in HIV-1 infection: systematic identification of optimal epitopes, vol. LAUR 97-1150. Los Alamos (NM): Los Alamos National Laboratory; 1997.
10. Buseyne F., Chaix M.L., Fleury B., Manigard O., Burgard M., Blanche S.et al. Riviere Y. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. Virology. 250:1998;316-324.
11. Caley I.J., Betts M.R., Irlbeck D.M., Davis N.L., Swanstrom R., Frelinger J.A.et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71:1997;3031-3038.
12. Cease K., Berzofsky J. Toward a vaccine for AIDS: the emergence of immunobiology based vaccine development. Ann. Rev. Immunol. 12:1994;923-989.
13. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C.et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1998;1230-1246.
14. Cohen J. AIDS research. Debate begins over new vaccine trials. Science 2001;Sep. 14:293.
15. Colombani J., Lepage V., Degos L., Kalil J., Fellous M. HLA monoclonal antibody registry: a proposal. Tissue Antigens. 20:1982;161-171.
16. De Groot AS, Bosma A, Chinai N, Frost J, Jesdale BM, Gonzalez MA, et al. From genome to vaccine: in silico predictions, ex vivo verification. Vaccine 2001;19(31):4385-95.
17. De Groot A.S., Jesdale B.M., Szu E., Schafer J.R., Chicz R., Deocampo G. An interactive web site providing MHC ligand predictions: application to HIV research. AIDS Res. Hum. Retroviruses. 7:1997;139-142.
18. De Groot A.S., Saint Aubin C., Bosma A., Sbai H., Rayner J., Martin W. Rapid determination of HLA B*07 ligands from the West Nile virus NY99 genome. Emerg. Infect. Dis. 7:2001;706-713.
19. Evans D.T., O'Connor D.H., Jing P., Dzuris J.L., Sidney J., das Silva J.et al. Virus-specific CTL responses selected for amino-acid variation in simian immunodeficiency virus env and nef. Nat. Med. 5:1999;1270-1276.
20. Ferrari G., Kostyu D.D., Cox J., Dawson D.V., Flores J., Weinhold K.J.et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. AIDS Res. Hum. Retroviruses. 16:2000;1433-1443.
21. Ferrari G., Humphrey W., McElrath M.J., Excler J.L., Duliege A.M., Clements M.L.et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte responses in uninfected volunteers. Proc. Natl. Acad. Sci. U.S.A. 94:1997;1396-1401.
22. Foung SK, Taidi B, Ness D, Grumet FC. A monoclonal antibody against HLA A11 and A24. Hum Immunol 1986;15:316-9.
23. Gianfrani C., Oseroff C., Sidney J., Chestnut R.W., Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Hum. Immunol. 61:2000;438-452.
24. Goulder P.J., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A.et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:1997;212-217.
25. Hanke T., McMichael A.J. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat. Med. 6:2000;951-955.
26. Haynes B.F. HIV vaccines: where we are and where we are going. Lancet. 348:1996;933-937.
27. Hu D.J., Dondero T.J., Rayfield M.A., George J.R., Schochetmen E.A. The emerging genetic diversity of HIV. JAMA. 275:1996;210-216.
28. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J. Dramatic rise in plasma viremia after CD8 (+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189:1999;991-998.
29. Jin X., Nixon D.F., Roberts C.G.P., Nixon D.F., Safrit J., Zhang L.Q.et al. Identification of subdominant cytotoxic T lymphocyte epitopes encoded by autologous HIV type 1 sequences, using dendritic cell stimulation and computer-driven algorithm. AIDS Res. Hum. Retroviruses. 16:2000;67-76.
30. Johnson R.P., Trocha A., Yang L., Mazarra G.P., Panicali D.L., Buchanan T.M.et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes: fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. J. Immunol. 147:1991;1512.
31. Lieberman J. The cytotoxic T cell response to HIV-1. In: Huber ME, Wahn P, editors, Proceedings of the Symposium in Immunology V. Berlin: Springer-Verlag; 1996.
32. Lieberman J., Fabry J.A., Fong D.M., Parkerson G.R.R. Recognition of a small number of diverse epitopes dominates the cytotoxic T lymphocyte response to HIV type 1 in an infected individual. AIDS Res. Hum. Retroviruses. 13:1997;383-392.
33. Lieberman J., Fabry J.A., Kuo M.C., Earl P., Moss B., Skolnik P.R. Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in Gp160 and reverse transcriptase. J. Immunol. 148:1992;2738-2747.
34. Ljunggren H.G., Stam N.J., Ohlen C., Neefjes J.J., Hoglund P., Heemels M.T.et al. Empty MHC class I molecules come out in the cold. Nature. 346:1990;476-480.
35. Lynch J.A., deSouza M., Robb M.D., Markowitz L., Nitayaphan S., Sapan C.V.et al. Cross-clade cytotoxic T cell response to human immunodeficiency virus type 1 proteins among HLA disparate North Americans and Thais. J. Infect. Dis. 178:1998;1040-1046.
36. McMichael A.J., Phillips R.E. Escape of HIV from immune control. Ann. Rev. Immunol. 15:1997;271-296.
37. Meister G.E., Roberts C.G.P., Berzofsky J.A., De Groot A.S. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine. 13(6):1995;581-591.
38. Nijman H.W., Houbiers J.G.A., Vierboom M.P.M., van der Burg S.H., Drijfhout J.W., D'Amaro J.et al. Identification of peptide sequences that potentially trigger HLA A2.1-restricted cytotoxic T lymphocytes. Eur. J. Immunol. 23:1993;1215-1219.
39. Parham P., Brodsky F.M. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA A2 and a variant of HLA A28. Hum. Immunol. 3:1981;277-299.
40. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Imunogenetics 1999;50(3-4):213-9.
41. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
42. Rowland-Jones S., Dong T., Krausa P., Sutton J., Newell H., Ariyoshi K. et al. The role of cytotoxic T-cells in HIV infection. Dev. Biol. Standard. 92:1998;209-214.
43. Rowland-Jones S.L., Dong T., Fowke K.R., Kimani J., Krausa P., Newell H.et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102:1998;1758-1765.
44. Schmechel S.C., Russell N., Hladik F., Lang J., Wilson A., Ha R.et al. Immune defense against HIV-1 infection in HIV-1-exposed seronegative persons. Immunol. Lett. 79:2001;21-27.
45. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A.et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 283:1999;857-860.
46. Shankar P, Fabry JA, Fong DM, Lieberman J. Three regions of HIV-1 gp160 contain clusters of immunodominant CTL epitopes, Immunol Lett 1996;52:23-30.
47. Storkus W.J., Alexander J., Payne J.A., Cresswell P., Dawson J.R. The alpha 1/alpha 2 domains of class I HLA molecules confer resistance to natural killing. Immunology. 143:1989;3853-3857.
48. Threlkeld S.C., Wentworth P.A., Kalams S.A., Wilkes B.M., Ruhl D.J., Keogh E.et al. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily. J. Immunol. 159:1997;1648-1657.
49. WHO-UNAIDS, VAC. Approaches to the development of broadly protective HIV vaccines: challenges posed by the genetic, biological and antigenic variability of HIV-1. AIDS 2001;15:W1-25.
50. Wilson S.E., Pedersen S.L., Kunich J.C., Wilkins V.L., Mann D.L., Mazzara G.P.et al. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection. AIDS Res. Hum. Retroviruses. 14:1998;925-937.
51. Wolfel C., Drexler I., Van Pel A., Thres T., Leister N., Herr W.et al. Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope. Int. J. Cancer. 88:2000;432-438.
52. Zhang Q.J., Gavioli R., Klein G., Masucci M.G. An HLA A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc. Natl. Acad. Sci. U.S.A. 90:1993;2217-2221.
53. De Groot AS, Sbai H, Saint Aubin C, McMurry JA, Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol Cell Biol 2002;80(3):255-69.